Cardio Diagnostics (CDIO) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Insight Molecular Diagnostics is the larger company by market cap ($113.2 million vs $5.8 million), about 19.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | IMDX |
|---|---|---|
| Share price | $1.96 | $3.46 |
| Market cap | $5.80M | $113.23M |
| 1-day change | -2.00% | +2.37% |
| YTD return | — | -53.87% |
| 1-year return | — | -5.98% |
| 5-year return | — | -94.91% |
| EPS (TTM) | $-2.87 | $-1.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $8.51 |
| 52-week low | $0.97 | $2.42 |
| Distance from 52-week high | -75.22% | -59.34% |
| Average volume | 55.78K | 234.39K |
| Shares outstanding | 2.96M | 32.72M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 19.5 times larger than Cardio Diagnostics by market value ($113.23M vs $5.80M).
CDIO vs IMDX FAQ
Which is bigger, Cardio Diagnostics or Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $113.23M compared with $5.80M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.